[Chemotherapy for B lymphoid malignancy in childhood--results in BLK88 protocol].

Abstract

Ten cases of newly diagnosed pediatric B cell non-Hodgkin's lymphoma or acute lymphoblastic leukemia (B-NHL, stage I & II 6 cases, stage III & IV 2 cases/ALL 2 cases) experienced during the last 7 years (1987-1994) were treated by BLK88 protocol, which consisted of HD-CPM (1,200 mg/m2), and HD-MTX (1,000 mg/m2) with VCR, ADR, and/or AraC combination, and CNS prophylaxis by triple intrathecal injection. The therapy duration was 24 weeks for B-NHL (36 weeks for B-ALL). The results showed that while one of the six cases in stage I & II relapsed, and other 4 cases of stage III & IV B-NHL/ALL remained in complete remission. On the other hand, all of the four cases in stage III & IV in historical controls had relapsed. Neutropenia and liver dysfunction were observed during therapy, but they were tolerable. We conclude that BLK88 is a very useful protocol for B-NHL/ALL in childhood.

• Authors: S Hibi, F Fujiwara, T Hashida, T Matsumura, S Todo, T Sawada, S Imashuku
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 37 Issue 4 Pg. 297-302 (Apr 1996) ISSN: 0485-1439 [Print] Japan
• PMID: 8847799 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Vincristine
• Doxorubicin
• Cyclophosphamide
• Methotrexate

Topics

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Child, Preschool
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Humans
• Injections, Spinal
• Lymphoma, B-Cell (drug therapy)
• Male
• Methotrexate (administration & dosage)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy)
• Vincristine (administration & dosage)